Want to see ATNM full AI Analyst Report?
ATNM Stock Chart & Stats
$0.86
-$0.03(-3.48%)
At close: 4:00 PM EDT
$0.86
-$0.03(-3.48%)
Day’s Range― - ―
52-Week Range$0.74 - $1.81
Previous Close$0.86
Volume113.35K
Average Volume (3M)208.30K
Market Cap
$30.31M
Enterprise Value-$8.61M
Total Cash (Recent Filing)$36.47M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)2.9
Beta1.76
Next Earnings
Nov 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding31,441,437
10 Day Avg. Volume380,172
30 Day Avg. Volume208,296
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.42
Price to Sales (P/S)471.40
P/FCF Ratio-1.72
Enterprise Value/Market Cap-0.28
Enterprise Value/Revenue-0.25
Enterprise Value/Gross Profit-0.24
Enterprise Value/Ebitda-0.71
Forecast
1Y Price Target
$3.50Price Target Upside306.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low debt and a material increase in shareholders' equity meaningfully reduce solvency risk for a clinical-stage biotech. This capital base improves the firm's ability to fund trials or negotiate non-dilutive partnerships, sustaining operations over the medium term despite cash burn.
Step-up In TTM Revenue And Positive Net IncomeA sizable, recent revenue increase and reported positive net income show improved commercial or milestone-based inflows. That enhances strategic flexibility, can de-risk near-term funding needs, and supports continued investment in core programs if the trend persists beyond one reporting period.
Radioconjugate Platform And Advancing PipelineProgress on multiple radioconjugate candidates and new preclinical results expand the company's scientific moat and addressable indications. A diversified pipeline and platform capabilities increase the probability of at least one durable commercial product or lucrative partnership/licensing outcomes.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained, large negative operating and free cash flows indicate the business is not self-funding; this elevates the need for external capital and raises dilution and execution risk. Continued cash burn can constrain R&D pacing and strategic optionality over the medium term.
Extremely Thin Gross Margin And Mixed Profitability QualityA very low gross margin implies limited ability to convert revenue into sustainable operating profits and suggests revenue may be one-off or milestone-driven. This undermines earnings durability and raises questions about scalable economics if commercial revenues replace milestone payments.
NYSE American Listing Compliance RiskActive exchange noncompliance and a remediation timeline inject structural uncertainty into capital access and investor confidence. Potential delisting risk can materially reduce liquidity, raise financing costs, and limit strategic transactions, hindering long-term program execution.
Actinium Pharmaceuticals News
ATNM FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $0.73 and its highest was $1.80 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Actinium Pharmaceuticals’s market cap is $30.31M.
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Nov 23, 2026 which is in 100 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.187 by -$0.003.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,441,437 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.187. Following the earnings report the stock price went down -1.77%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Currently, no hedge funds are holding shares in ATNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapy (radioconjugate) treatments for cancer, with an emphasis on hematologic malignancies and conditioning regimens for bone marrow (hematopoietic stem cell) transplantation. The company’s lead development programs include Iomab-B, an iodine-131–based targeted conditioning therapy for patients with relapsed or refractory acute myeloid leukemia (AML) undergoing transplant, and Actimab-A, an actinium-225–based radioconjugate therapy being studied in AML and other settings. Actinium also develops additional radioconjugate candidates and associated platform capabilities for delivering radioisotopes to cancer targets.
ATNM Stock 12 Month Forecast
Average Price Target
$3.50
▲(306.98% Upside)
Technical Analysis
Cellectar Biosciences
―
PDS Biotechnology
―
GT Biopharma
―
Marker Therapeutics
―
Celularity
―
Ownership Overview
0.59% Insiders
5.48% Mutual Funds
1.32% Other Institutional Investors
88.22% Public Companies and
Individual Investors